

ISOLAGEN INC  
Form 8-K  
December 03, 2008

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): DECEMBER 3, 2008**

**ISOLAGEN, INC.**

(Exact name of registrant as specified in its charter)

**DELAWARE**

(State or other Jurisdiction of  
Incorporation)

**001-31564**

(Commission File Number)

**87-0458888**

(IRS Employer Identification No.)

**405 EAGLEVIEW BLVD., EXTON, PA**

(Address of Principal Executive Offices)

**19341**

(Zip Code)

Registrant's telephone number, including area code: **(484) 713-6000**

**NOT APPLICABLE**

(Former name or former address if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other Events**

Isolagen, Inc. ( Company ) disclosed in its Form 10-Q for the quarter ended September 30, 2008 that it had not paid an interest payment of \$1.6 million that was due on November 3, 2008. No event of default occurred with respect to the unpaid interest as the Company's related indenture agreement defines an interest payment default as a failure in the payment of any interest when it becomes due and payable, and continuance of such default for a period of 30 days. The Company has made the interest payment within the 30 day time period allotted by the indenture, and therefore is not in default with respect to the indenture.

**SIGNATURE**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ISOLAGEN, INC.

Date: December 3, 2008

By: /s/ Todd J. Greenspan

Todd J. Greenspan,  
Chief Financial Officer